Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 4975 | 2011 |
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 4322 | 2018 |
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 3665 | 2018 |
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 3659 | 2016 |
Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3297 | 2014 |
Early childhood development coming of age: science through the life course MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ... The Lancet 389 (10064), 77-90, 2017 | 2649 | 2017 |
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ... Nature 515 (7528), 558-562, 2014 | 2569 | 2014 |
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2053 | 2017 |
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1342 | 2018 |
Erdafitinib in locally advanced or metastatic urothelial carcinoma Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ... New England Journal of Medicine 381 (4), 338-348, 2019 | 1076 | 2019 |
Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 974 | 2020 |
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 655 | 2017 |
Enfortumab vedotin in previously treated advanced urothelial carcinoma T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ... New England Journal of Medicine 384 (12), 1125-1135, 2021 | 604 | 2021 |
Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... European urology 71 (2), 151-154, 2017 | 452 | 2017 |
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial J Rodon, JC Soria, R Berger, WH Miller, E Rubin, A Kugel, A Tsimberidou, ... Nature medicine 25 (5), 751-758, 2019 | 414 | 2019 |
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ... Annals of oncology 24 (7), 1807-1812, 2013 | 413 | 2013 |
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 392 | 2021 |
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 377 | 2020 |
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients D Planchard, Y Loriot, F Andre, A Gobert, N Auger, L Lacroix, JC Soria Annals of Oncology 26 (10), 2073-2078, 2015 | 325 | 2015 |
TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint … ST Tagawa, AV Balar, DP Petrylak, AR Kalebasty, Y Loriot, A Fléchon, ... Journal of Clinical Oncology 39 (22), 2474, 2021 | 310 | 2021 |